U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pubmed/26345206

Tetraprenylacetone (Geranylgeranylacetone) is an anti-peptic ulcer drug developed and approved in Japan in 1984. Tetraprenylacetone is shown to suppress H. pylori induced tissue and cell injury and inflammatory reaction, so it is expected to show beneficial effects on H. pylori-infected tissues. Tetraprenylacetone is used to treat patients suffering from peptic ulcers and gastritis. In Japan it is sold under the brand name Selbex.

CNS Activity

Curator's Comment: GGA (Tetraprenylacetone) is able to pass through blood brain barrier

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Selbex

Approved Use

Improvement of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases: Acute gastritis and acute exacerbation stage of chronic gastritis and Gastric ulcers

Launch Date

1984
Primary
Selbex

Approved Use

Improvement of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases: Acute gastritis and acute exacerbation stage of chronic gastritis and Gastric ulcers

Launch Date

1984
PubMed

PubMed

TitleDatePubMed
Suppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in mice.
2013
Geranylgeranylacetone induces apoptosis via the intrinsic pathway in human melanoma cells.
2016 Aug
Patents

Patents

Sample Use Guides

Capsules 50 mg: The usual adult dosage for oral use is 3 capsules (150 mg of teprenone) daily in three divided doses after meals. The dosage may be adjusted depending on the patient’s age and symptoms. Fine Granules 10%: The usual adult dosage for oral use is 1.5 g (150 mg of teprenone) daily in three divided doses after meals. The dosage may be adjusted depending on the patient’s age and symptoms.
Route of Administration: Oral
In Vitro Use Guide
Human melanoma cell lines G361, SK-MEL-2, and SK-MEL-5 were treated with GGA (Tetraprenylacetone) at various doses (1-100uM). GGA significantly reduced the viability of G361, SK-MEL-2, and SK-MEL-5 human melanoma cells at concentrations above 10uM.
Name Type Language
TEPRENONE
INCI   INN   JAN   MART.   MI   WHO-DD  
INN   INCI  
Official Name English
teprenone [INN]
Common Name English
SELBEX
Brand Name English
Teprenone [WHO-DD]
Common Name English
TEPRENONE [MART.]
Common Name English
TEPRENONE [JAN]
Common Name English
TEPRENONE [INCI]
Common Name English
GERANYLGERANYLACETONE
Common Name English
5,9,13,17-NONADECATETRAEN-2-ONE, 6,10,14,18-TETRAMETHYL-, MIXTURE OF (5Z,9E,13E) AND ALL TRANS (5E,9E,13E)
Common Name English
5,9,13,17-NONADECATETRAEN-2-ONE, 6,10,14,18-TETRAMETHYL-
Common Name English
TEPRENONE [MI]
Common Name English
E-0671
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 743920
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
FDA ORPHAN DRUG 742220
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
FDA ORPHAN DRUG 744620
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
NCI_THESAURUS C29701
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
Code System Code Type Description
INN
5412
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
CHEBI
31649
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
WIKIPEDIA
Teprenone
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
FDA UNII
S8S8451A4O
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
MERCK INDEX
m10566
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY Merck Index
DAILYMED
S8S8451A4O
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
NCI_THESAURUS
C66587
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
EVMPD
SUB15486MIG
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL79686
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
RXCUI
1362746
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
2596
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
CAS
6809-52-5
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID6048620
Created by admin on Fri Dec 15 16:25:40 GMT 2023 , Edited by admin on Fri Dec 15 16:25:40 GMT 2023
PRIMARY
All of the following components must be present:
Definition References